Mastek Ltd Q4 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/irsp7p23pyi4ecfcy66mih5l.pdf

Key Takeaways


Demand Environment

Hiral Chandrana: "We still see uncertainty in terms of the organization and the changes that they have. But we have seen a bottoming out in terms of our position, in that account."

US Business: Disappointment & Reset

Hiral Chandrana: "Many of the investments are going right up to the CEO or even to the board, in terms of approval cycles. And so that, I think, is a trend that we will see at least for the next two to three quarters."

Oracle & Salesforce: The Growth Engines

Hiral Chandrana: "No, we expect both Oracle and Salesforce, both which constitutes a reasonable portion, anywhere from 45% to 47% for overall business. We expect both those to continue to grow higher than our company average."

Margins & Cost Structure

Arun Agarwal: "We believe that that's a good range to operate around, and we want to operate in that range. Definitely in the mid to long-term, we want to come back to the higher EBITDA profile as we start achieving our growth target."

Vertical & Geographic Mix

Vertical / GeographyTrendCommentary
UK Secure Government▲ Strong growthSolid in-quarter execution, not a blip; work of national critical importance; diversifying into police, biometrics, DWP, councils.
Middle-East▲ Positive surpriseReduced accounts but revenue uptick; good order book momentum; digital services gaining traction in ServiceNow, Microsoft, Snowflake.
US▼ DisappointingOracle Cloud commerce drop and decision delays; foundational pieces expected to convert to growth in FY24.
BFSI / Professional Services▬ Account-specificGrowth driven by one very large US-headquartered organization with a deal win and ramp-up; not broad-based across the industry.
UK Health (NHS)▼ Bottomed, uncertainConservative baseline reset for FY24; potential upside if NHS opens spend, but probability assumed very low.
US & ME Healthcare▲ High potentialOracle-Cerner acquisition and Salesforce payer/payvider capabilities create FY24 opportunity; Banner Health as vetted case study.
UK Private Sector▲ Stabilized, uptickingDefended real estate, reached stabilization mid-year, then saw decent upticks; growth area for FY24 but not top-three priority.

Balance Sheet & Cash Flow


Guidance & Commitments

CommitmentSpecificsTimeline
FY24 growthIndustry-leading or a few percentage points above industry year-on-year growth; benchmarks against Tier 1 and larger Indian IT (7-9% range) plus mid/small-cap peersFY24
Oracle & Salesforce growthBoth to grow higher than company average, faster than FY24FY24
US deal sizesAverage deal size much larger than FY23; deals larger than $1 crore an aspiration; overall order intake much betterFY24
Free cash flow recoveryReturn to 75-80% of operating cash flow rangeFY24
US decision cyclesLonger approval cycles (CEO/board level) to persistAt least next 2-3 quarters
UK government market shareGains expected from large framework participationNext 1-2 years
NHS contributionConservative baseline assumed; probability of deal spend treated as very lowFY24
EBITDA marginOperate in high-teens range; mid-to-long-term return to higher EBITDA profile as growth targets achievedMid-to-long-term (no specific date)

Key Metrics

MetricQ4 FY23
Operating revenue₹709 cr, +7.7% QoQ and +22% YoY in INR terms; +5.3% QoQ in constant currency
Full-year FY23 revenue growth18.5% in constant currency
Operating EBITDA margin17.7%, +40 bps QoQ
Full-year FY23 operating EBITDA margin~17.8%
PAT₹72.6 cr, +8.2% QoQ
12-month order backlog$280 million, +5.2% QoQ and +22% YoY; +17.2% YoY in constant currency
12-month order backlog (INR)₹1,794 cr, committed over next 12 months
Gross cash₹270 cr vs ₹325 cr in December 2022
Attrition (LTM)21%, a drop of 700 bps from a year ago
Clients added28 during the quarter
Oracle and Salesforce combined revenue share45% to 47% of overall business
MST acquisition performance118% of the acquisition plan delivered
DSO93 days, improved from 98 days in the prior quarter
Cash flow from operations (full year FY23)₹100 cr vs ₹270 cr in the prior year